Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
SpaceX Shares Surge as Wall Street Backs AI Growth Potential 
Sanrio Shares Plunge as Q1 Profit Miss Overshadows Strong Sales 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Add as a preferred source on Google
Novartis AG announced on Monday, Feb. 5, that it has acquired MorphoSys. The Basel, Switzerland-based pharmaceutical corporation agreed to buy the cancer drug developer for $2.9 billion or €2.7 billion.
As per Reuters, Novartis will offer shareholders €68 per share in cash. It also revealed its plan to take MorphoSys private once the deal is completed. Upon closing the transaction, which is expected within the first two quarters of this year, Novartis will now own pelabresib.
MorphoSys' Pelabresib Drug
This treatment has been described as one of the most promising cancer drugs. It is used to combat life-threatening forms of the intrusive disease. It was mentioned that pelabresib could be used for the treatment of rare bone marrow cancer called myelofibrosis and other types of lumpy lymphomas.
Through its purchase of MorphoSys, Novartis can bolster its oncology portfolio. This merger marks Novartis's first M&A deal this year. It was speculated earlier in January that it would buy Cytokinetics biotech firm, but the deal did not proceed.
Details of Transaction
Their respective Board unanimously approved the acquisition deal between Novartis and MorphoSys of Directors. While awaiting the final closing of the transaction, MorphoSys will continue to operate its business independently.
"We are excited about the opportunity of bringing pelabresib, a potential next-generation treatment combined with ruxolitinib, to people living with myelofibrosis, a rare and debilitating form of blood cancer," Novartis' president of development and chief medical officer, Shreeram Aradhye, M.D., said in a press release. "With the planned acquisition of MorphoSys, we aim to further strengthen our leading pipeline and portfolio in oncology, adding to our capabilities and expertise."
He added, "Building on our long-standing development partnership with MorphoSys, we look forward to continuing our work together to realize the full impact and value of their investigational medicines for patients with unmet needs."
Photo by: Novartis Media Library
